Reduction of uric acid levels with allopurinol treatment improves endothelial function in patients with chronic kidney disease

Clinical Nephrology

Volumn 77, Issue 4, 2012, Pages 275-282

  Yelken, Berna ^a   Caliskan, Yasar ^a   Gorgulu, Numan ^a   Altun, Ibrahim ^a   Yilmaz, Akar ^a   Yazici, Halil ^a   Oflaz, Huseyin ^a   Yildiz, Alaattin ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Allopurinol; Chronic kidney disease; Endothelial dysfunction; Oxidative stress; Uric acid

Indexed keywords

3 NITROTYROSINE; ADVANCED OXIDATION PROTEIN PRODUCT; ALBUMIN; ALLOPURINOL; C REACTIVE PROTEIN; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; REACTIVE OXYGEN METABOLITE; TRIACYLGLYCEROL; URIC ACID; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE CLEARANCE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERURICEMIA; ISCHEMIA; MALE; OXIDATIVE STRESS; PROTEINURIA; TRIACYLGLYCEROL BLOOD LEVEL; VASODILATATION;

ADOLESCENT; ADULT; ALBUMINS; ALGORITHMS; ALLOPURINOL; BIOLOGICAL MARKERS; BODY MASS INDEX; C-REACTIVE PROTEIN; CREATININE; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERURICEMIA; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; P-GLYCOPROTEIN; PROSPECTIVE STUDIES; REACTIVE OXYGEN SPECIES; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME; TYROSINE; URICOSURIC AGENTS;

EID: 84861502810     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN107352     Document Type: Article

References (51)

1. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998; 9 (Suppl): S16-S23. PubMed
2. Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet. 2000; 356: 147-152. doi:10.1016/S0140-67 36(00)02456-9 PubMed
3. Drey N, Roderick P, Mullee M, Rogerson M. A population-based study of the incidence and outcomes of diagnosed chronic kidney disease. Am J Kidney Dis. 2003; 42: 677-684. doi:10.1016/S0 272-6386(03)00916-8 PubMed
4. Henry RM, Kostense PJ, Bos G, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD. Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study. Kidney Int. 2002; 62: 1402-1407. doi:10.1111/j.1523-1755.2002.kid571.x PubMed
5. Manjunath G, Tighiouart H, Coresh J, Macleod B, Salem DN, Griffith JL, Levey AS, Sarnak MJ. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int. 2003; 63: 1121-1129. doi:10.1046/j.1523-1755. 2 003.00838.x PubMed
6. Muntner P, He J, Hamm L, Loria C, Whelton PK. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol. 2002; 13: 745-753. PubMed
7. Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lameire N; European Uremic Toxin Work Group. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant. 2005; 20: 1048-1056. doi:10. 10 93/ndt/gfh813 PubMed
8. Shlipak MG, Fried LF, Cushman M, Manolio TA, Peterson D, Stehman-Breen C, Bleyer A, Newman A, Siscovick D, Psaty B. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA. 2005; 293: 1737-1745. doi:10.1001/jama.293.14.1737 Pub Med
9. Muntner P, He J, Astor BC, Folsom AR, Coresh J. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol. 2005; 16: 529-538. doi:10.1681/ASN.2004080656 PubMed
10. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002; 62: 1524-1538. doi:10. 1046/j.1523-1755.2002.00600.x PubMed
11. Anker SD, Doehner W, Rauchhaus M, Sharma R, Francis D, Knosalla C, Davos CH, Cicoira M, Shamim W, Kemp M, Segal R, Osterziel KJ, Leyva F, Hetzer R, Ponikowski P, Coats AJ. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation. 2003; 107: 1991-1997. doi:10.1161/01.CIR.0000065637. 105 1 7.A0 PubMed
12. Clive DM. Renal transplant-associated hyperuricemia and gout. J Am Soc Nephrol. 2000; 11: 974-979. PubMed
13. Lin HY, Rocher LL, McQuillan MA, Schmaltz S, Palella TD, Fox IH. Cyclosporine-induced hyperuricemia and gout. N Engl J Med. 1989; 321: 287-292. doi:10.1056/NEJM198908033210504 Pub Med
14. Edvardsson VO, Kaiser BA, Polinsky MS, Palmer JA, Quien R, Baluarte HJ. Natural history and etiology of hyperuricemia following pediatric renal transplantation. Pediatr Nephrol. 1995; 9: 57-60. doi:10.1007/BF00858973 PubMed
15. Gertler MM, Garn SM, Levine SA. Serum uric acid in relation to age and physique in health and in coronary heart disease. Ann Intern Med. 1951; 34: 1421-1431. PubMed
16. Klein R, Klein BE, Cornoni JC, Maready J, Cassel JC, Tyroler HA. Serum uric acid. Its relationship to coronary heart disease risk factors and cardiovascular disease, Evans County, Georgia. Arch Intern Med. 1973; 132: 401-410. doi:10.1001/archinte.132.3.401 PubMed
17. Burack RC, Keller JB, Higgins MW. Cardiovascular risk factors and obesity: are baseline levels of blood pressure, glucose, cholesterol and uric acid elevated prior to weight gain? J Chronic Dis. 1985; 38: 865-872. doi:10.1016/0021-9681 (85) 90111-0 PubMed
18. Woo J, Swaminathan R, Cockram C, Lau E, Chan A. Association between serum uric acid and some cardiovascular risk factors in a Chinese population. Postgrad Med J. 1994; 70: 486-491. doi:10.1136/pgmj.70.825.486 PubMed
19. Iribarren C, Folsom AR, Eckfeldt JH, McGovern PG, Nieto FJ. Correlates of uric acid and its association with asymptomatic carotid atherosclerosis: the ARIC Study. Atherosclerosis Risk in Communities. Ann Epidemiol. 1996; 6: 331-340. doi:10.1016/S1047-2797(96)00052-X PubMed
20. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med. 1999; 131: 7-13. PubMed
21. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA. 2000; 283: 2404-2410. doi:10.1001/jama. 283.18.2404 PubMed
22. Dounousi E, Papavasiliou E, Makedou A, Ioannou K, Katopodis KP, Tselepis A, Siamopoulos KC, Tsakiris D. Oxidative stress is progressively enhanced with advancing stages of CKD. Am J Kidney Dis. 2006; 48: 752-760. doi:10.1053/j. ajkd.2006.08.015 PubMed
23. Ferretti G, Bacchetti T, Masciangelo S, Pallotta G. Lipid peroxidation in hemodialysis patients: effect of vitamin C supplementation. Clin Biochem. 2008; 41: 381-386. doi:10.1016/j.clinbiochem. 2007.12.011 PubMed
24. Fortuño A, Beloqui O, San José G, Moreno MU, Zalba G, Díez J. Increased phagocytic nicotinamide adenine dinucleotide phosphate oxidasedependent superoxide production in patients with early chronic kidney disease. Kidney Int Suppl. 2005; 99: S71-S75. doi:10.1111/j.1523-1755. 20 05 .09913.x PubMed
25. Moncada S. Nitric oxide: discovery and impact on clinical medicine. J R Soc Med. 1999; 92: 164-169. PubMed
26. Sies H. Oxidative stress: oxidants and antioxidants. Exp Physiol. 1997; 82: 291-295. PubMed
27. Vaziri ND. Roles of oxidative stress and antioxidant therapy in chronic kidney disease and hypertension. Curr Opin Nephrol Hypertens. 2004; 13: 93-99. doi:10.1097/00041552-200401000-00013 PubMed
28. Himmelfarb J, Hakim RM. Oxidative stress in uremia. Curr Opin Nephrol Hypertens. 2003; 12: 593-598. doi:10.1097/00041552-200311000-000 04 PubMed
29. Methe H, Weis M. Atherogenesis and inflammation-was Virchow right? Nephrol Dial Transplant. 2007; 22: 1823-1827. doi:10.1093/ndt/gfm 112 PubMed
30. Merino A, Nogueras S, Buendía P, Ojeda R, Carracedo J, Ramirez-Chamond R, Martin-Malo A, Aljama P. Microinflammation and endothelial damage in hemodialysis. Contrib Nephrol. 2008; 161: 83-88. doi:10.1159/000130412 PubMed
31. Stenvinkel P. Endothelial dysfunction and inflammation-is there a link? Nephrol Dial Transplant. 2001; 16: 1968-1971. doi:10.1093/ndt/16.10.1968 PubMed
32. Zhang DX, Gutterman DD. Mitochondrial reactive oxygen species mediated signaling in endothelial cells. Am J Physiol. 2007; 292: H2023-H2031.
33. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992; 340: 1111-1115. doi:10.1016/0140-6736(92)93147-F PubMed
34. Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, Krotova K, Block ER, Prabhakar S, Johnson RJ. Hyperuricemia induces endothelial dysfunction. Kidney Int. 2005; 67: 1739-1742. doi:10.1111/j.1523-1755.2005.00273.x PubMed
35. Erdogan D, Gullu H, Caliskan M, Yildirim E, Bilgi M, Ulus T, Sezgin N, Muderrisoglu H. Relationship of serum uric acid to measures of endothelial function and atherosclerosis in healthy adults. Int J Clin Pract. 2005; 59: 1276-1282. doi:10.1111/j.1742-1241.2005.00621.x PubMed
36. Doehner W, Schoene N, Rauchhaus M, Leyva-Leon F, Pavitt DV, Reaveley DA, Schuler G, Coats AJ, Anker SD, Hambrecht R. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation. 2002; 105: 2619-2624. doi:10.1161/01.CIR. 000 00 17502.58595.ED PubMed
37. Mercuro G, Vitale C, Cerquetani E, Zoncu S, Deidda M, Fini M, Rosano GM. Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk. Am J Cardiol. 2004; 94: 932-935. doi:10.1016/j.amjcard.2004.06.032 PubMed
38. Newland H. Hyperuricemia in coronary, cerebral and peripheral arterial disease: an explanation. Med Hypotheses. 1975; 1: 152-155. doi:10. 1016/0306-9877(75)90011-0 PubMed
39. Niskanen LK, Laaksonen DE, Nyyssönen K, Alfthan G, Lakka HM, Lakka TA, Salonen JT. Uric acid level as a risk factor for cardiovascular and allcause mortality in middle-aged men: a prospective cohort study. Arch Intern Med. 2004; 164: 1546-1551. doi:10.1001/archinte.164.14. 1546 PubMed
40. Menon V, Gul A, Sarnak MJ. Cardiovascular risk factors in chronic kidney disease. Kidney Int. 2005; 68: 1413-1418. doi:10.1111/j.1523-1755. 2005.00551.x PubMed
41. Zoccali C, Mallamaci F, Tripepi G. Traditional and emerging cardiovascular risk factors in endstage renal disease. Kidney Ibt. 2003; 63 (s85): 105-110. doi:10.1046/j.1523-1755.63.s85.25.x
42. Farquharson CAJ, Butler R, Hill A, Belch JJ, Struthers AD. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation. 2002; 106: 221-226. doi:10.1161/01.CIR.000 0022140.61460.1D PubMed
43. Butler R, Morris AD, Belch JJ, Hill A, Struthers AD. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension. 2000; 35: 746-751. PubMed
44. Guthikonda S, Sinkey C, Barenz T, Haynes WG. Xanthine oxidase inhibition reverses endothelial dysfunction in heavy smokers. Circulation. 2003; 107: 416-421. doi:10.1161/01.CIR.0000046 448. 26751.58 PubMed
45. George J, Carr E, Davies J, Belch JJ, Struthers A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation. 2006; 114: 2508-2516.
46. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol. 1996; 271: C1424-C1437. PubMed
47. Hazen SL, Zhang R, Shen Z, Wu W, Podrez EA, MacPherson JC, Schmitt D, Mitra SN, Mukhopadhyay C, Chen Y, Cohen PA, Hoff HF, Abu-Soud HM. Formation of nitric oxide-derived oxidants by myeloperoxidase in monocytes: pathways for monocyte-mediated protein nitration and lipid peroxidation In vivo. Circ Res. 1999; 85: 950-958. PubMed
48. Ignarro LJ, Napoli C, Loscalzo J. Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview. Circ Res. 2002; 90: 21-28. doi:10.1161/hh0102.102330 PubMed
49. Morris ST, Jardine AG. The vascular endothelium in chronic renal failure. J Nephrol. 2000; 13: 96-105. PubMed
50. Blantz RC, Lortie M, Vallon V, Gabbai FB, Parmer RJ, Thomson S. Activities of nitric oxide in normal physiology and uremia. Semin Nephrol. 1996; 16: 144-150. PubMed
51. van Guldener C, Lambert J, Janssen MJFY, Donker AJ, Stehouwer CD. Endothelium-dependent vasodilatation and distensibility of large arteries in chronic haemodialysis patients. Nephrol Dial Transplant. 1997; 12 (Suppl 2): 14-18. PubMed